PET/CT Scans for Prostate Cancer Patients at Risk of Recurrence Offered at Loyola

PET/CT Scans for Prostate Cancer Patients at Risk of Recurrence Offered at Loyola
Detecting the exact location and extent of prostate cancer that has returned and metastasized in patients after initial treatment is now more likely, following the recent approval of a new positron emission tomography (PET) scan tracer that accurately targets prostate cancer cells. Loyola Medicine announced it is using the new tracer, and is the first center in the Midwest to offer PET/CT scans to patients with prostate cancer. "We are delighted that we can now offer PET/CT scans to prostate cancer patients in order to improve the quality of their care,” Robert Wagner, MD, medical director of nuclear medicine at the Loyola University Chicago Stritch School of Medicine, said in a press release. Patients diagnosed with prostate cancer are initially treated with either surgery, cryotherapy, or radiation. But the cancer can reappear in some patients, detected through an increase in prostate specific antigen (PSA) levels. But elevated PSA levels only imply the likelihood of recurrent cancer, and give no hint as to its spread. "By knowing where the cancer has gone, we can provide more accurate, precise and selective treatment,” said Bital Savir-Baruch, MD, a Loyola nuclear physician. PET/CT scans are usually very accurate in detecting cancer cells, being able to detect cancer earlier than other imaging techniques, such as computed tomography (CT) or magnetic resonance imaging (MRI). They rely on a tracer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *